Journals
Publish with us
Publishing partnerships
About us
Blog
Disease Markers
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Disease Markers
/
2018
/
Article
/
Tab 3
/
Research Article
IgG Antibodies to GlcNAc
β
and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment
Table 3
Association of the level of anti-GlcNAc
β
Abs and ALP with the stages of fibrosis.
Parameter
Genotype
Stage (
)
Median (
)
Anti-GlcNAc
β
1b
0
0.155
1–3
0.377
0.055 (F0
vs.
F1–3)
1–4
0.389
0.021 (F0
vs.
F1–4)
ALP
1b
0
67
1–4
80
0.025 (F0 vs. F1–4)
0–1
67
2–4
86
0.002 (F0–1 vs. F2–4)
1b and 3a
0
67
1–4
81
0.008 (F0 vs. F1–4)
0–1
68
2–4
86
0.001 (F0–1 vs. F2–4)